Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. (ABBV) is a global biopharmaceutical leader driving innovation in immunology, oncology, and neuroscience therapies. This page provides real-time access to AbbVie's official press releases, regulatory milestones, and strategic developments.
Investors and industry professionals will find a curated collection of earnings reports, FDA approval updates, clinical trial results, and partnership announcements. Our comprehensive resource eliminates the need to track multiple sources, offering verified information directly from corporate communications and trusted financial publications.
Key content includes updates on AbbVie's R&D pipeline, mergers & acquisitions like the Allergan integration, patent developments, and market expansion initiatives. All materials are organized chronologically for efficient analysis of the company's trajectory.
Bookmark this page for streamlined monitoring of AbbVie's operational and financial performance. Check back regularly to stay informed about developments impacting one of the pharmaceutical sector's most influential innovators.
Allergan Aesthetics, part of AbbVie (NYSE: ABBV), has launched a promotion offering double Allē points for consumers who receive treatments with JUVÉDERM® fillers. This initiative runs until September 30, 2022, and allows users to earn points redeemable for future treatments. The JUVÉDERM® Collection is the leading dermal filler brand in the U.S., targeting signs of aging with immediate, natural-looking results. The market potential is significant, with an estimated 20 million U.S. consumers interested in filler treatments in the next two years.
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), has received U.S. FDA approval for JUVÉDERM® VOLUX™ XC, the first hyaluronic acid filler designed specifically to enhance jawline definition in adults over 21. This innovation marks the sixth product in the JUVÉDERM® portfolio, which includes renowned fillers like JUVÉDERM® VOLUMA® XC. Clinical studies show that 69.9% of participants experienced significant improvement in jawline definition after six months, with high satisfaction rates. JUVÉDERM® VOLUX™ XC will be available to consumers in early 2023, following comprehensive training for healthcare providers.
AbbVie reported a strong second quarter ending June 30, 2022, with a diluted EPS of $0.51 (up 21.4%) and an adjusted diluted EPS of $3.37 (up 11.2%). Net revenues hit $14.583 billion, a 4.5% increase, bolstered by a 17.8% rise in immunology portfolio revenues. Key products like Skyrizi and Rinvoq saw substantial growth, contributing to expectations of $7.5 billion in combined annual sales. The company confirmed its 2022 adjusted EPS guidance of $13.78-$13.98.
AbbVie announced that the European Commission has approved RINVOQ® (upadacitinib 15 mg, once daily) as the first JAK inhibitor for treating active non-radiographic axial spondyloarthritis (nr-axSpA) in the EU. This approval is based on the Phase 3 SELECT-AXIS 2 trial, where RINVOQ showed significant disease control with nearly half of patients achieving ASAS40 response at week 14. RINVOQ is also approved for ankylosing spondylitis and has received a label enhancement for patients inadequately responding to biologic therapies.
AbbVie (NYSE: ABBV) announced the submission of applications to the U.S. FDA and European Medicines Agency for upadacitinib (RINVOQ®) to treat adults with moderately to severely active Crohn's disease. This follows successful results from three Phase 3 clinical trials showing significant improvements in clinical remission and endoscopic response. The safety profile of upadacitinib remained stable with no new risks identified. These developments reflect AbbVie's commitment to innovation in treating inflammatory bowel disease.
The European Commission has approved RINVOQ (upadacitinib) for adults with moderately to severely active ulcerative colitis, marking its fifth indication in the EU. This decision is supported by three Phase 3 studies demonstrating significant clinical remission, response, and mucosal healing at weeks 8 and 52. Specifically, 26-33% of patients achieved clinical remission at week 8 during induction, and 42-52% at week 52 during maintenance, compared to 4-12% for placebo. Safety results were consistent with prior data, with no new significant risks identified.
AbbVie and Allergan Aesthetics will present over 30 abstracts at the TOXINS 2022 Conference from July 27-30 in New Orleans. Key topics include clinical studies on onabotulinumtoxinA (BOTOX) for chronic migraine, cervical dystonia, and aesthetic applications. Noteworthy presentations include findings from the CD-PROBE study analyzing onabotulinumtoxinA's safety and efficacy in cervical dystonia. AbbVie emphasizes its ongoing commitment to neurotoxin research and enhancing patient outcomes through medical education, showcasing advancements in both therapeutic and aesthetic domains.
AbbVie has announced a strategic alliance with iSTAR Medical to develop and commercialize the MINIject® device, a minimally invasive glaucoma surgical device. This partnership aims to enhance AbbVie's eye care portfolio and improve treatment options for glaucoma patients. The agreement includes a $60M upfront payment to iSTAR Medical, which will continue its development until the completion of the STAR-V clinical study. AbbVie holds an exclusive right to acquire iSTAR Medical, with potential contingent payments of up to $475M based on certain milestones.
Genmab A/S (Nasdaq: GMAB) announced that AbbVie (NYSE: ABBV) will submit a conditional marketing authorization application (MAA) to the European Medicines Agency for epcoritamab to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in H2 2022. This follows Genmab's intention to submit a biologics license application (BLA) to the FDA for the same drug. The MAA is supported by preliminary efficacy results from the EPCORE™ NHL-1 trial, emphasizing the significant medical need for new treatment options for patients with DLBCL.
AbbVie has submitted a marketing authorization application (MAA) to the European Medicines Agency for atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist aimed at preventing migraines in adults experiencing at least four migraine days per month. This follows two pivotal Phase 3 studies indicating atogepant's efficacy; the ADVANCE trial showed significant reductions in mean monthly migraine days, while the PROGRESS study confirmed similar success for chronic migraine patients. If approved, atogepant would be the first daily oral CGRP receptor antagonist in Europe.
